- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.09. | EU clears first drug therapy for rare disease cALD | ||
| 25.09. | FDA starts speedy review of Imfinzi in bladder cancer | ||
| 25.09. | FDA nominee Overton dodges questions on Trump influence | ||
| 25.09. | Wnt drug gives MSD first eye disease win after EyeBio deal | ||
| 24.09. | Australia starts probe into AI infiltration of Medicare | ||
| 24.09. | Lilly's rival to Novo's new Awiqli insulin gets FDA approval | ||
| 24.09. | Kyverna builds case for CAR-T in stiff person syndrome | ||
| 24.09. | Lilly forges $3.35bn alliance with China's InnoCare | ||
| 24.09. | Grail cancer test gets lukewarm backing from FDA adcomm | ||
| 23.09. | AI specialists Enveda and Basecamp rake in the cash | ||
| 23.09. | Roche, Viking Therapeutics, and Syntis showcase obesity drug candidates | ||
| 23.09. | Roche's IgAN hopeful sefaxersen passes phase 3 test | ||
| 23.09. | Amgen's Horizon buyout delivers Sjögren's disease win | ||
| 23.09. | Pharma leaders urge Europe to halt 'slow agony' of decline | ||
| 23.09. | UK issues £45m funding call for research partnerships | ||
| 22.09. | UK needs 'clearer path for dementia diagnosis and treatment' | ||
| 22.09. | Iambic files IPO after signing up AbbVie as new partner | ||
| 22.09. | UK first country to launch CSL's trivalent flu shot Aujemflu | ||
| 22.09. | Advocacy group pokes holes in Trump's MFN pricing claims | ||
| 21.09. | ADARx, Trex Bio, and Retension Pharma take aim at IPOs | ||
| 21.09. | Beacon's XLRP gene therapy set for filing after phase 3 win | ||
| 21.09. | Under pressure, Novo lays out blockbuster launch plans | ||
| 21.09. | Telix to buy radiopharma rival ITM for $1.65bn upfront | ||
| 21.09. | AZ's gMG drug Klygefa nears EU approval | ||
| 18.09. | Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.